Matthias Staehelin

"Matthias Staehelin has an impressive transactional and intellectual property practice that he leverages to support clients in a variety of financing, dealmaking and life sciences issues."

Matthias Staehelin is primarily involved in the life sciences and IT industries; he regularly advises on the sale and purchase of companies (M&A), financing through investors (private equity and venture capital), licensing and collaboration agreements (including joint ventures), introductions to the stock exchange (IPOs) and restructuring.

• NBE Therapeutics sold to Boehringer Ingelheim for EUR 1.1bn
• Sale of Symetis to Boston Scientific for USD 435m
• Polyphor grants Fosun Pharma license for China
• Collaboration of AC Immune with Lilly
• Numerous financing transactions (Noema Pharma 54m, Polyneuron Pharmaceuticals 36.5m, NBE Therapeutics 40 m,

• Capital markets: Equity
• M&A
• Private equity
• Private equity funds
• Restructuring and insolvency

• Healthcare
• Industrials
• Pharma and life sciences
• Real estate

• BioValley Basel Association (President)
• BioValley Business Angels Club (BioBAC) (Board Member)

• University of Basel (Dr. iur., 1993)
• College: Internationalisierung des Privatrechts Freiburg i.B. (1992/93)
• College of Europe, Bruges (Master of Advanced European Studies, 1992/Diplome des Hautes Etudes Europeennes, 1991)
• University of Basel (lic. iur., 1990)